DFTX — Definium Therapeutics, Inc.

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum d… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$22.05
Market Cap$2.53B
Float98.8M
Shares Outstanding109.1M
Dividend RateNone

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$34.1M N/A -$33.6M
2021 N/A -$93.0M N/A -$91.2M
2022 N/A -$56.8M N/A -$63.2M
2023 N/A -$95.7M -$3.2M -$92.6M
2024 N/A -$109M -$527,000 -$106M
2025 N/A -$184M N/A -$178M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 N/A -$23.3M
Jun 2025 N/A -$42.7M
Sep 2025 N/A -$67.3M
Dec 2025 N/A -$50.4M

Ownership & Float

Insider Ownership0.9%
Institutional Ownership66.7%
Short Float9.9%
% of All Funds Holding2.20%
Number of Funds Holding170

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$20.31Near-term / short-term trend
Weekly40-Week SMA$14.64Medium-term trend
Weekly80-Week SMA$10.93Cyclical trend (business cycle)
Weekly200-Week SMA$7.53Secular trend (multi-year)
Monthly10-Month SMA$15.81Near-term monthly trend
Monthly20-Month SMA$11.40Medium-term monthly trend
Monthly40-Month SMA$8.33Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$13.50 support 1.39x 3 months ago
$11.70 support 1.52x 6 months ago
$8.80 support 1.02x 7 months ago

Historical Earnings Reactions (35 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 1.66% 0.00% 45.71% 34.27% -13.46%
1 Day 0.53% 0.00% 40.00% 17.48% -13.46%
1 Week 5.07% -2.73% 42.86% 71.15% -15.47%
2 Weeks 3.13% -3.27% 45.71% 60.78% -23.53%
1 Month 8.69% -3.49% 37.14% 223.53% -31.03%

Next earnings: May 14, 2026 (3 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan6.4%50.0%10
Feb10.0%70.0%10
Mar104.3%50.0%10
Apr2.1%60.0%10
May-5.1%22.2%9
Jun-10.0%44.4%9
Jul-2.0%44.4%9
Aug39.1%44.4%9
Sep-4.2%33.3%9
Oct5.2%66.7%9
Nov6.8%33.3%9
Dec10.6%60.0%10

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.67% 42.1% 444
Tuesday 1.40% 41.9% 489
Wednesday 1.08% 38.6% 487
Thursday 0.10% 40.6% 478
Friday 9.97% 42.2% 479

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 66.7%

Insider Transactions — Smart Summary

Total insider ownership: 0.9%

Founder-led management: Scott Freeman (Co-Founder & Clinical Advisor), Leonard Latchman (Co-Founder)

12-Month Insider Activity Summary

Total Filings3
Net Value-$796,998.97
Net Shares Change-43,151
% of Float-0.0%
C-Suite Filings3
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Barrow Robert Chief Executive Officer -$451,240.57 1 N/A
Sullivan Mark Chief Legal Officer -$197,665.94 1 N/A
Karlin Daniel Chief Medical Officer -$148,092.46 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-03-26 – 2026-03-26 3 3 -$796,998.97 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-26 Sullivan Mark Chief Legal Officer -$197,665.94 Transaction at $18.47, now +19.4%
2026-03-26 Barrow Robert Chief Executive Officer -$451,240.57 Transaction at $18.47, now +19.4%
2026-03-26 Karlin Daniel Chief Medical Officer -$148,092.46 Transaction at $18.47, now +19.4%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Definium Therapeutics, Inc. (DFTX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for DFTX on Trend Edge →